ClinicalTrials.gg
Active, not recruitingNCT05572515MajesTEC-9Updated Nov 4, 2026

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Teclistamab and Pomalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 211 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 4, 20265 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing teclistamab in Multiple Myeloma — 22 open to participants now, 32 under way, 9 of them phase 3. teclistamab · Multiple Myeloma.

Enrollment
6th of 33
614 · median 80
Started
2023
with 3 others
Phase 3
8 of 33
4 open now
Primary completion
2025-10
later than 4 of 31 live
Registered
7th of 33
by date
Lead sponsor
7 of 33
Janssen Research & Development, LLC

Among the 33 studies testing teclistamab in Multiple Myeloma, this one is the 6th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, reaches primary completion later than 4 of the 31 other live ones, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

22 of the 33 studies testing teclistamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About teclistamab

teclistamab: first FDA approval 2022 (TECVAYLI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing teclistamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
  • Documented evidence of progressive disease or failure to achieve a response to last based on investigator's determination of response by International myeloma working group (IMWG) criteria
  • Have an (ECOG) performance status score of 0 to 2
  • A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
  • Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • Received any prior B cell maturation antigen (BCMA)-directed therapy
  • A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) or life-threatening allergies, , or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
  • Received a maximum cumulative dose of of >=140 mg of prednisone or equivalent within 14 days prior to randomization
  • Received a live, attenuated vaccine within 4 weeks before randomization
  • Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
  • Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    Teclistamab

    Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study.

    Drug: Teclistamab

  • Experimental
    Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)

    Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study. Participants who are still receiving the treatment and benefiting from it may enter the LTE and DA-LTE Phases to continue their current treatment until end of the study.

    Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone · Drug: Carfilzomib

Interventions

  • Teclistamab will be administered subcutaneously.

    Also known as: JNJ-64007957

  • Pomalidomide will be administered orally.

  • Bortezomib will be administered subcutaneously.

  • Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.

  • Carfilzomib will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. Part 1: Progression-free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 9 years

  2. Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity

    Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to \[\>=\] 38°C); Grade 2: Fever (Temperature \>=38°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature \>=38°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature \>=38°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death.

    Time frame: Up to 9 years

Secondary outcomes

  1. Part 1 and 2: Overall Response (Partial Response [PR] or Better)

    Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

    Time frame: Up to 9 years

  2. Part 1 and 2: Very Good Partial Response (VGPR) or Better Response

    VGPR or better (Stringent Complete Response \[sCR\]+Complete Response \[CR\]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

    Time frame: Up to 9 years

  3. Part 1 and 2: Complete Response (CR) or Better Response

    CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

    Time frame: Up to 9 years

  4. Part 1: Duration of Response (DOR)

    DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first.

    Time frame: Up to 9 years

  5. Part 1: Time to Next Treatment (TTNT)

    TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment.

    Time frame: Up to 9 years

  6. Part 1: Progression-free Survival on Next-line Therapy (PFS2)

    PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.

    Time frame: Up to 9 years

  7. Part 1: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of the participant's death due to any cause.

    Time frame: Up to 9 years

  8. Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity

    Number of participants with AEs by Severity will be reported.

    Time frame: Up to 9 years

  9. Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity

    Number of participants with SAEs by Severity will be reported.

    Time frame: Up to 9 years

  10. Part 1 and 2: Number of Participants with Abnormal Laboratory Results

    Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported.

    Time frame: Up to 9 years

  11. Part 1 and 2: Serum Concentrations of Teclistamab

    Serum concentrations of teclistamab will be reported.

    Time frame: Up to 9 years

  12. Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab

    Number of participants with ADAs to teclistamab will be reported.

    Time frame: Up to 9 years

  13. Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)

    Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Baseline up to 9 years

  14. Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score

    Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.

    Time frame: Baseline up to 9 years

  15. Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.

    Time frame: Baseline up to 9 years

  16. Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)

    Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline up to 9 years

  17. Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL

    Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change.

    Time frame: Up to 9 years

  18. Part 1: PFS in Participants in High-risk Molecular Features

    PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 9 years

  19. Part 1: Depth of Response in Participants in High-risk Molecular Features

    Depth of response in participants in high-risk molecular features will be reported.

    Time frame: Up to 9 years

07

Study locations

211 sites

Showing the first 100 of 211 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegard M, Wang D, Pei L, Wroblewski S, Aries IM, Quijano Carde NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O; MajesTEC-9 Trial Investigators. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. N Engl J Med. 2026 Jul 30;395(5):440-453. doi: 10.1056/NEJMoa2603870. Epub 2026 May 29. PubMed 42212933 ↗

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Oct 2025, 30 months.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 30 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2022
First posted
Oct 7, 2022
StartActual
Mar 29, 2023
Primary completionActual
Oct 13, 2025
CompletionEst.
Aug 31, 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (4 Brazil, 1 India)
  • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer · Curitiba, Brazil
  • IDOR - Regional Bahia · Salvador, Brazil
  • Funfarme Sjrp · São José do Rio Preto, Brazil
  • IDOR - Regional Sao Paulo · São Paulo, Brazil
  • Fortis Memorial Research Institute · Gūrgaon, India
Show 5 removed
  • Liga Paranaense de Combate ao Cancer · Curitiba, Brazil
  • Hospital Sao Rafael · Salvador, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base · São José do Rio Preto, Brazil
  • Instituto D Or de Pesquisa e Ensino IDOR · São Paulo, Brazil
  • Fortis Memorial Research Institute · Gurgaon, India
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    5 sites added, 5 sites removed
    Show 5 added (4 Brazil, 1 India)
    • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer · Curitiba, Brazil
    • IDOR - Regional Bahia · Salvador, Brazil
    • Funfarme Sjrp · São José do Rio Preto, Brazil
    • IDOR - Regional Sao Paulo · São Paulo, Brazil
    • Fortis Memorial Research Institute · Gūrgaon, India
    Show 5 removed
    • Liga Paranaense de Combate ao Cancer · Curitiba, Brazil
    • Hospital Sao Rafael · Salvador, Brazil
    • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base · São José do Rio Preto, Brazil
    • Instituto D Or de Pesquisa e Ensino IDOR · São Paulo, Brazil
    • Fortis Memorial Research Institute · Gurgaon, India
    + 6 other changes: index terms, identifiers, verification date, conditions, arm descriptions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05572515
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
Mar 29, 2023
Primary completion
Oct 13, 2025
Completion
Aug 31, 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teclistamab · Pomalidomide · Bortezomib · Dexamethasone · Carfilzomib

Start the discussion